Publications
Curated papers, preprints, and external literature that frame carbon utilization, lipid pathways, and SAF-relevant feedstock development.
Selected references will be added as the platform narrative and partner materials mature.
Resources
A working knowledge base for the SAF-first commercialization thesis behind C1 Foundry.
This page gives technical funders, SAF partners, and industrial collaborators a clearer view of the platform logic, operating assumptions, and open questions behind the company's first market focus.
Categories
Organize the evidence, assumptions, and open questions that matter for SAF-oriented partnership decisions.
The categories below frame the materials needed for disciplined external review: SAF ecosystem context, feedstock logic, technical rationale, and operating questions that affect commercialization.
Developing
Patents
A place for issued or filed intellectual property materials once there is enough substance to share responsibly around pathway design and process integration.
Public IP materials will be listed here when they are appropriate for external review.
Presentations
Technical overviews, ecosystem briefings, and presentation materials intended for serious external review.
Partner-facing briefings will be added as they are ready for external circulation.
Technical Notes
Focused memos that explain SAF feedstock logic, pathway assumptions, process constraints, and commercialization framing.
Technical notes will appear here as the first platform documents are prepared for external readers.
FAQs
A structured set of questions and answers for technical funders, SAF partners, and industrial collaborators evaluating the company closely.
See the FAQ section below for current working answers.
How to use this page
Treat this as a diligence surface, not a marketing archive.
The point is to separate documented evidence, operating assumptions, and questions that still require direct validation. For a SAF-oriented carbon conversion company, that distinction matters. A useful resource page should sharpen those boundaries, not blur them.
As materials are added, this hub can hold primary references, SAF ecosystem briefings, technical memos, and structured documents that support serious diligence conversations.
FAQ
Questions technical funders, SAF partners, and industrial collaborators are likely to ask early.
These answers are intentionally concise. They clarify C1 Foundry's current thinking without overstating what has already been proven on commercialization, scale, or economics.
Why start with SAF feedstocks?
SAF feedstocks provide a sharper first market than a generic platform story. Aviation decarbonization pressure is high, downstream refining pathways already exist, and there is meaningful demand for lower-carbon feedstock options. That does not prove the route works economically. It only makes the commercialization question more concrete.
Why focus on feedstocks instead of trying to make finished SAF?
A feedstock company has a narrower and more realistic first job than a refinery company. The immediate challenge is to produce intermediates or lipids that can enter existing SAF upgrading pathways. Trying to own the entire refining stack too early would add commercial and capital burdens before the core biological system is ready.
Why does acetate still matter if SAF is the first wedge?
Acetate matters because it may offer a more tractable intermediate between C1 carbon utilization and downstream lipid synthesis. It is not valuable on its own. It matters only if it improves the full system by easing metabolic constraints or simplifying the route to a useful SAF-relevant feedstock.
Where do the techno-economic constraints show up?
The hard parts usually appear in productivity, energy demand, hydrogen availability, gas handling, recovery cost, capital intensity, and downstream fit with refining infrastructure. A route can look strong in stoichiometric terms and still fail once those constraints are considered together.
Why are CO2 and related C1 inputs still central to the platform?
They remain central because they are the technical basis of the broader platform vision. The commercialization focus on SAF feedstocks does not replace that foundation. It narrows the first market question while keeping CO2 utilization, acetate intermediates, and cofeeding logic relevant to the long-term platform.
What is proven versus still unresolved?
The field has established important building blocks around C1 conversion, lipid metabolism, and engineered production pathways. What remains unresolved at the company level is the integrated commercialization claim: a specific route that can deliver the right molecule, at useful productivity, with manageable recovery and credible economics for SAF feedstock markets.